<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6108">
  <stage>Registered</stage>
  <submitdate>23/08/2016</submitdate>
  <approvaldate>23/08/2016</approvaldate>
  <nctid>NCT02920541</nctid>
  <trial_identification>
    <studytitle>Dose-escalation Study of Oral Administration of S 055746 in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome</studytitle>
    <scientifictitle>Phase I Dose-escalation Study of the Orally Administered Selective Bcl-2 Inhibitor S 055746 as Monotherapy for the Treatment of Patients With Acute Myeloid Leukaemia (AML) or High or Very High Risk Myelodysplastic Syndrome (MDS)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2014-002559-24</secondaryid>
    <secondaryid>CL1-055746-002</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Acute Myeloid Leukaemia (AML)</healthcondition>
    <healthcondition>Myelodysplastic Syndrome (MDS)</healthcondition>
    <conditioncode>
      <conditioncode1>Other</conditioncode1>
      <conditioncode2>Research that is not of generic health relevance and not applicable to specific health categories listed above</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Acute leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Chronic leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Children's - Leukaemia &amp; Lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Haematological diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Other blood disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - S 055746

Experimental: S 055746 - 


Treatment: drugs: S 055746
S 055746, per os administration, from 50 to 2000 mg once a day during a 21-day cycle. Participants will receive 21-day cycles of treatment until a discontinuation criterion is met.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Maximum Tolerated Dose (MTD) - MTD is the highest drug dosage that is unlikely (&lt;25% posterior probability) to cause DLT in more than 33% of the treated patients in the first cycle of S 055746 treatment.</outcome>
      <timepoint>During cycle 1 (21 days)</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Incidence of Adverse Events (AEs) - Characterized by severity and seriousness of AEs, laboratory abnormalities and other safety parameters such as electrocardiogram (ECG) changes</outcome>
      <timepoint>From first dose until 30 days after the last dose intake</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma concentration of S 055746</outcome>
      <timepoint>Pre-dose on Cycle 1 Day 1 (C1D1), C1D2, C1D3, C1D8, C1D9, C2D1 ; 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10-12 hours post-dose on C1D1, C1D8</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The pharmacokinetic (PK) profile of S 055746: Area Under the Curve [AUC]</outcome>
      <timepoint>Pre-dose on Cycle 1 Day 1 (C1D1), C1D2, C1D3, C1D8, C1D9, C2D1 ; 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10-12 hours post-dose on C1D1, C1D8</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The PK profile of S 055746: Maximal Concentration [Cmax]</outcome>
      <timepoint>Pre-dose on Cycle 1 Day 1 (C1D1), C1D2, C1D3, C1D8, C1D9, C2D1 ; 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10-12 hours post-dose on C1D1, C1D8</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacodynamic (PD) parameter: bone marrow gene expression of Bcl-2 family members</outcome>
      <timepoint>At Cycle 1 D1 pre-dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PD parameter: bone marrow protein expression of Bcl-2 family members</outcome>
      <timepoint>At Cycle 1 D1 pre-dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PD parameter: gene alteration analysis of Bcl-2 family members and other genes of interest</outcome>
      <timepoint>At Cycle 1 D1 pre-dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Best Response Rate (BRR)</outcome>
      <timepoint>Up to study completion (maximum of 3 years)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progression Free Survival (PFS)</outcome>
      <timepoint>From date of inclusion until the date of progression or date of death, whichever occurs first, assessed up to study completion (maximum of 3 years)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Event Free Survival (EFS)</outcome>
      <timepoint>From date of inclusion until the date of progression or date of death or discontinuation of treatment, whichever occurs first, assessed up to study completion (maximum of 3 years)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Women or men aged &gt;= 18 years

          -  Patients with cytologically confirmed and documented de novo, secondary or
             therapy-related AML excluding acute promyelocytic leukaemia:

               -  with relapsed or refractory disease or

               -  &gt; or = 65 years not previously treated for AML, who are not candidates for
                  intensive chemotherapy or not candidates for standard chemotherapy

          -  Patients with cytologically confirmed and documented MDS or non proliferative Chronic
             Myelomonocytic Leukaemia (CMML) in relapse or refractory after previous treatment line
             including at least one hypomethylating agent therapy:

               -  with high or very high risk MDS and without established alternative therapy

               -  transformed to AML and without established alternative therapy

          -  Ability to swallow oral tablet(s)

          -  World Health Organization (WHO) performance status 0-2

          -  Circulating white blood cells &lt; or = 30 x 10^9 /L and &lt; or = 13 x10^9 for non
             proliferative CMML

          -  Adequate renal and hepatic functions

          -  Negative serum pregnancy test within 7 days prior to the first day of study drug
             administration

          -  Patients must use effective contraception

          -  Written informed consent</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Foreseeable poor compliance to the study procedures

          -  Legally incapacitated person under guardianship or trusteeship

          -  Pregnant or breast-feeding women

          -  Participation in therapeutic interventional study involving investigational drug
             intake at the same time or within 2 weeks or at least 5 half-lives or patient already
             enrolled

          -  Previous treatment with a BH3 mimetic

          -  Patients who have not recovered to baseline or CTCAE&lt; or = Grade 1 from toxicity due
             to all prior therapies received for the studied disease

          -  Any previous anti-leukaemic treatment for the studied disease within at least 5
             half-lives or 2 weeks (hydroxycarbamide permitted)

          -  Any radiotherapy within 4 weeks before first intake (except palliative radiotherapy at
             localized lesions)

          -  Major surgery within 3 weeks before first intake of S 055746

          -  Allogenic stem cell transplant within 6 months before the first intake of S 055746 and
             for patients who still need immunosuppressive treatment

          -  Leukaemic leptomeningeal or leukaemic central nervous system involvement

          -  Concomitant uncontrolled infection, organ dysfunction or medical disease likely to
             interfere with evaluation of S 055746 safety or study outcome

          -  Human immunodeficiency virus (HIV) infection, hepatitis B or active hepatitis C
             infection

          -  Within 6 months prior to the first intake of S 055746, history of myocardial
             infarction, acute coronary syndromes (including unstable angina), coronary
             angioplasty, and/or stenting, ischemic/haemorrhagic stroke, atrial fibrillation,
             digestive haemorrhagic risk, deep venous/arterial thromboembolic complication or
             bleeding diathesis

          -  Decreased Left Ventricular Ejection Fraction (LVEF)

          -  QTcF prolongation

          -  Patients who are receiving QT prolonging drug

          -  Coagulopathies with increased risk of bleeding complications

          -  Other malignancy within 2 years prior to the first intake

          -  Strong or moderate CYP3A4 inhibitors or inducers (treatment, food or drink products)
             within 7 days prior to the first intake

          -  Treatment highly metabolised by the CYP3A4 or CYP2D6 and/or with a narrow therapeutic
             index, multi-enzymes and/or OATP substrates or herbal products within 7 days prior to
             the first intake.

          -  Patients receiving proton pump inhibitor</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>80</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/08/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>The Alfred Hospital - Melbourne</hospital>
    <hospital>Royal Melbourne Hospital - Parkville</hospital>
    <postcode> - Melbourne</postcode>
    <postcode> - Parkville</postcode>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Marseille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Pierre BÃ©nite</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Institut de Recherches Internationales Servier</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine the safety profile and tolerability of S 055746 in
      patients with AML, and high or very high risk MDS, in terms of Dose-Limiting Toxicities
      (DLTs), Maximum Tolerated Dose (MTD) and determine the Recommended Phase 2 Dose (RP2D)
      through safety profile (DLT, MTD), PK profile, PD profile and preliminary efficacy.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02920541</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Andrew Wei, MBBS, PhD</name>
      <address>The Alfred</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Institut de Recherches Internationales Servier</name>
      <address />
      <phone>+33 1 55 72 43 66</phone>
      <fax />
      <email>clinicaltrials@servier.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>